Acute Coronary SyndromePOC-ETNCT05665127
Point of Care Evaluation of High-sensitivity Cardiac Troponin
An observational study of Acute Coronary Syndrome, run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
In this observational research project the investigators wish to test new technologies that could allow them to either detect or rule out heart attacks earlier. Currently, when a patient attends the Emergency Department with symptoms that could be due to a heart attack, the patient has a blood test taken from a vein… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Coronary Syndrome
- How many people
- 1,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 16 Nov 2022to 28 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients with suspected acute coronary syndrome attending the Emergency Department or Acute Medical Unit
Who may be able to join
- Presenting to hospital with symptoms of suspected acute coronary syndrome
- Age 18 years and over
Who cannot join
- Patients with ST-segment elevation on the electrocardiogram
- Patients presenting with an out-of-hospital cardiac arrest
- Patients unable or unwilling to give informed consent
- Patients unable or unwilling to comply with study protocol
- Previous enrolment in this study
Trial locations and contacts
1 site in 1 country.
About this study
In this observational research project the investigators wish to test new technologies that could allow them to either detect or rule out heart attacks earlier.
Currently, when a patient attends the Emergency Department with symptoms that could be due to a heart attack, the patient has a blood test taken from a vein in the arm. This is sent to a laboratory to measure the level of a protein called troponin that is released from the heart when it is damaged. Doctors and nurses use the level of troponin measured in that blood sample, along with a tracing of the heart and an assessment of symptoms, to decide whether the patient is having a heart attack. On average, it takes about 2 hours from the patient arriving at hospital to the doctor or nurse receiving the blood test result so they can make this diagnosis.
Read more
A device has been designed that can measure troponin by using a drop of blood from a finger prick with the result available in around 10 minutes. This means that if a patient is having a heart attack we can diagnose it earlier and give them treatment. Previous studies have also showed that the majority of patients who attend hospital with chest pain ultimately do not have a heart attack. With this new device the investigators hope to be able to reassure these patients that their symptoms are not due to a heart attack, so the clinical team can concentrate on finding out what else could be causing their chest pain, and ultimately discharge them earlier.
The investigators aim to find the best way to use this new device and look at the impact this device has on the length of time from sample to diagnosis and time spent in hospital.
- Conditions
- Acute Coronary Syndrome
- Medical subject headings
- Acute Coronary Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
Type 1, 4b or 4c myocardial infarction or cardiac death
Measured: Index presentation to 30 days
Secondary outcomes (7)
Any myocardial infarction
Measured: Index presentation to 1 year
Cardiac death
Measured: Index presentation to 1 year
Any myocardial infarction or cardiac death
Measured: Index presentation to 1 year
Cardiovascular death
Measured: Index presentation to 1 year
All-cause death
Measured: Index presentation to 1 year
Reattendance with suspected acute coronary syndrome
Measured: Index presentation to 1 year
Unplanned coronary revascularization
Measured: Following index presentation to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2022
- Study start16 Nov 2022
- Primary completion28 Feb 2025
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromeStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Collaborators
- British Heart Foundation, NHS Grampian, Siemens Healthcare Diagnostics Ltd
- Responsible party
- Sponsor
- Investigators
- Nicholas Mills, Principal investigator, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05665127
- Sponsor's protocol ID
- AC21114
- Other IDs
- RG/20/10/34966
- Acronym
- POC-ET
- Status last verified
- Apr 2026
- First submitted
- 6 Dec 2022
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Point of Care Evaluation of High-sensitivity Cardiac Troponin
- ClinicalTrials.gov ID
- NCT05665127
- Acronym / sponsor ID
- POC-ET / AC21114
- Conditions
- Acute Coronary Syndrome
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Collaborators
- British Heart Foundation, NHS Grampian, Siemens Healthcare Diagnostics Ltd
- Study start
- 16 Nov 2022 (actual)
- Primary completion
- 28 Feb 2025 (actual)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 27 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this observational research project the investigators wish to test new technologies that could allow them to either detect or rule out heart attacks earlier.
Currently, when a patient attends the Emergency Department with symptoms that could be due to a heart attack, the patient has a blood test taken from a vein in the arm. This is sent to a laboratory to measure the level of a protein called troponin that is released from the heart when it is damaged. Doctors and nurses use the level of troponin measured in that blood sample, along with a tracing of the heart and an assessment of symptoms, to decide whether the patient is having a heart attack. On average, it takes about 2 hours from the patient arriving at hospital to the doctor or nurse receiving the blood test result so they can make this diagnosis.
A device has been designed that can measure troponin by using a drop of blood from a finger prick with the result available in around 10 minutes. This means that if a patient is having a heart attack we can diagnose it earlier and give them treatment. Previous studies have also showed that the majority of patients who attend hospital with chest pain ultimately do not have a heart attack. With this new device the investigators hope to be able to reassure these patients that their symptoms are not due to a heart attack, so the clinical team can concentrate on finding out what else could be causing their chest pain, and ultimately discharge them earlier.
The investigators aim to find the best way to use this new device and look at the impact this device has on the length of time from sample to diagnosis and time spent in hospital.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with suspected acute coronary syndrome attending the Emergency Department or Acute Medical Unit
Key inclusion criteria (2 listed)
- Presenting to hospital with symptoms of suspected acute coronary syndrome
- Age 18 years and over
Key exclusion criteria (5 listed)
- Patients with ST-segment elevation on the electrocardiogram
- Patients presenting with an out-of-hospital cardiac arrest
- Patients unable or unwilling to give informed consent
- Patients unable or unwilling to comply with study protocol
- Previous enrolment in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Type 1, 4b or 4c myocardial infarction or cardiac death
Time frame: Index presentation to 30 days
7 secondary outcomes
Any myocardial infarction
Time frame: Index presentation to 1 year
Cardiac death
Time frame: Index presentation to 1 year
Any myocardial infarction or cardiac death
Time frame: Index presentation to 1 year
Cardiovascular death
Time frame: Index presentation to 1 year
All-cause death
Time frame: Index presentation to 1 year
Reattendance with suspected acute coronary syndrome
Time frame: Index presentation to 1 year
Unplanned coronary revascularization
Time frame: Following index presentation to 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
Related trials for Acute Coronary Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicholas Mills principal investigator
University of Edinburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Coronary Syndrome, run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Type 1, 4b or 4c myocardial infarction or cardiac death (time frame: Index presentation to 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.